Cargando…

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo-controlled phase 3 trial evaluating the safety of resmetirom in adults with nonalcoholic fatty liver disease and presumed NASH. Patients were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harrison, Stephen A., Taub, Rebecca, Neff, Guy W., Lucas, K. Jean, Labriola, Dominic, Moussa, Sam E., Alkhouri, Naim, Bashir, Mustafa R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667098/ https://www.ncbi.nlm.nih.gov/pubmed/37845512 http://dx.doi.org/10.1038/s41591-023-02603-1

Ejemplares similares

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH
por: Harrison, Stephen A., et al.
Publicado: (2021)

Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis
por: Javanbakht, Mehdi, et al.
Publicado: (2022)

Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes
por: Alkhouri, Naim, et al.
Publicado: (2018)

Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?
por: Tomah, Shaheen, et al.
Publicado: (2020)

Ginger Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
por: Rahimlou, Mehran, et al.
Publicado: (2016)

Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease
por: Ahn, Sang Bong, et al.
Publicado: (2019)

Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD)
por: Alkhouri, Naim, et al.
Publicado: (2014)

Low Serum Potassium Levels Associated with Disease Severity in Children with Nonalcoholic Fatty Liver Disease
por: Tabbaa, Adam, et al.
Publicado: (2015)

Simple diagnostic algorithm identifying at-risk nonalcoholic fatty liver disease patients needing specialty referral within the United States
por: Alkhouri, Naim, et al.
Publicado: (2022)

Solubility determination, dissolution properties and solid transformation of resmetirom (form A) in heptane and seven alcohols
por: Liu, Chang, et al.
Publicado: (2023)

What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?
por: Alkhouri, Naim, et al.
Publicado: (2021)

The Development of the Pediatric NAFLD Fibrosis Score (PNFS) to Predict the Presence of Advanced Fibrosis in Children with Nonalcoholic Fatty Liver Disease
por: Alkhouri, Naim, et al.
Publicado: (2014)

A CONSORT-Compliant, Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Purified Anthocyanin in Patients With Nonalcoholic Fatty Liver Disease
por: Zhang, Pei-Wen, et al.
Publicado: (2015)

Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Karim, Gres, et al.
Publicado: (2023)

Effect of garlic powder consumption on body composition in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial
por: Soleimani, Davood, et al.
Publicado: (2016)

Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints
por: Alkhouri, Naim, et al.
Publicado: (2019)

Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled, phase II study
por: Yadav, Yogesh, et al.
Publicado: (2022)

The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database
por: Alkhouri, Naim, et al.
Publicado: (2022)

Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial
por: Ekhlasi, Golnaz, et al.
Publicado: (2016)

Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort
por: Khoudari, George, et al.
Publicado: (2019)

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis
por: Harrison, Stephen A., et al.
Publicado: (2022)

Effects of Pharmacologic Dose of Resveratrol Supplementation on Oxidative/Antioxidative Status Biomarkers in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Asghari, Somayyeh, et al.
Publicado: (2018)

Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner
por: Wang, Xiaojing, et al.
Publicado: (2023)

Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?
por: Noureddin, Nabil, et al.
Publicado: (2020)

Effect of Turmeric Supplementation on Blood Pressure and Serum Levels of Sirtuin 1 and Adiponectin in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial
por: Kalhori, Ali, et al.
Publicado: (2022)

Effect of garlic powder supplementation on blood pressure and hs‐C‐reactive protein among nonalcoholic fatty liver disease patients: A randomized, double‐blind, placebo‐controlled trial
por: Soleimani, Davood, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018
por: Truong, Emily, et al.
Publicado: (2022)

The Efficacy of Rosa damascena on Liver Enzymes in Nonalcoholic Fatty Liver Disease: A Randomized Double-Blind Clinical Trial
por: Moravej, S. Ali Al-Hadi, et al.
Publicado: (2021)

The Efficacy of Plantago major Seed on Liver Enzymes in Nonalcoholic Fatty Liver Disease: A Randomized Double-Blind Clinical Trial
por: Jazayeri, Seyedeh Ferdows, et al.
Publicado: (2021)

The effects of polyunsaturated fatty acids in alcohol dependence treatment - a double-blind, placebo-controlled pilot study
por: Fogaça, Marina N, et al.
Publicado: (2011)

Effects of Metformin on the Regulation of Free Fatty Acids in Insulin Resistance: A Double-Blind, Placebo-Controlled Study
por: Castro Cabezas, Manuel, et al.
Publicado: (2012)

Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Chong, Clara Yieh Lin, et al.
Publicado: (2020)

A double-blind placebo needle for acupuncture research
por: Takakura, Nobuari, et al.
Publicado: (2007)

Effect of silymarin on liver size and nonalcoholic fatty liver disease in morbidly obese patients: A randomized double-blind clinical trial
por: Atarodi, Hamed, et al.
Publicado: (2022)

Effects of cumin on nonalcoholic steatohepatitis: A double blind, randomised, controlled trial
por: Shavakhi, Ahmad, et al.
Publicado: (2015)

Schisandrin B: A Double-Edged Sword in Nonalcoholic Fatty Liver Disease
por: Leong, Pou Kuan, et al.
Publicado: (2016)

Effects of methylphenidate on the ERP amplitude in youth with ADHD: A double-blind placebo-controlled cross-over EEG study
por: Rubinson, Mica, et al.
Publicado: (2019)

Comparison of the efficacy of oral fenugreek seeds hydroalcoholic extract versus placebo in nonalcoholic fatty liver disease; a randomized, triple-blind controlled pilot clinical trial
por: Babaei, Amirhossein, et al.
Publicado: (2020)

The Efficacy of Pharmacological Treatment in Pediatric Nonalcoholic Fatty Liver Disease
por: Cho, Taeshik, et al.
Publicado: (2012)

Tocilizumab in severe COVID-19 – A randomized, double-blind, placebo-controlled trial
por: Malik, Muhammad Irfan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4852a7n8topc584n7daucgf6pm